These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22591029)

  • 21. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

  • 22. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.
    Ariceta G; Arrizabalaga B; Aguirre M; Morteruel E; Lopez-Trascasa M
    Am J Kidney Dis; 2012 May; 59(5):707-10. PubMed ID: 22196848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eculizumab. A less burdensome treatment for atypical haemolytic uraemic syndrome?
    Prescrire Int; 2013 Mar; 22(136):68. PubMed ID: 23593689
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful discontinuation of eculizumab therapy in a patient with aHUS.
    Pu JJ; Sido A
    Ann Hematol; 2014 Aug; 93(8):1423-5. PubMed ID: 24346709
    [No Abstract]   [Full Text] [Related]  

  • 25. [Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin].
    Beye F; Malbranche C; Tramecon D; Pernot C; Zanetta G; Mousson C; Guignard MH; Lazzarotti A
    Therapie; 2013; 68(2):119-22. PubMed ID: 23773354
    [No Abstract]   [Full Text] [Related]  

  • 26. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination.
    Struijk GH; Bouts AH; Rijkers GT; Kuin EA; ten Berge IJ; Bemelman FJ
    Am J Transplant; 2013 Mar; 13(3):819-20. PubMed ID: 23289494
    [No Abstract]   [Full Text] [Related]  

  • 27. [Eculizumab for atypical hemolytic uremic syndrome in newborn: a case report].
    Alonso-Triana YM; Perrino MJ
    Farm Hosp; 2015 Jul; 39(4):217-8. PubMed ID: 26276740
    [No Abstract]   [Full Text] [Related]  

  • 28. Eculizumab for congenital atypical hemolytic-uremic syndrome.
    Gruppo RA; Rother RP
    N Engl J Med; 2009 Jan; 360(5):544-6. PubMed ID: 19179329
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
    Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Loirat C
    N Engl J Med; 2013 Oct; 369(14):1379-80. PubMed ID: 24088105
    [No Abstract]   [Full Text] [Related]  

  • 31. Eculizumab in atypical hemolytic-uremic syndrome.
    Ring T
    N Engl J Med; 2013 Oct; 369(14):1377-8. PubMed ID: 24088106
    [No Abstract]   [Full Text] [Related]  

  • 32. Eculizumab in atypical hemolytic-uremic syndrome.
    Tanimoto T; Oshima Y; Kami M
    N Engl J Med; 2013 Oct; 369(14):1378-9. PubMed ID: 24088109
    [No Abstract]   [Full Text] [Related]  

  • 33. Eculizumab in atypical hemolytic-uremic syndrome.
    Amadio A; Tejani AM
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088107
    [No Abstract]   [Full Text] [Related]  

  • 34. Eculizumab in atypical hemolytic-uremic syndrome.
    Kistler AD
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088108
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.
    Chatelet V; Frémeaux-Bacchi V; Lobbedez T; Ficheux M; Hurault de Ligny B
    Am J Transplant; 2009 Nov; 9(11):2644-5. PubMed ID: 19775316
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hemolytic uremic syndrome as of 2013].
    Loirat C; Mariani-Kurkdjian P; Fremeaux-Bacchi V
    Arch Pediatr; 2013 Aug; 20(8):827-30. PubMed ID: 23835098
    [No Abstract]   [Full Text] [Related]  

  • 37. Transplantation in atypical hemolytic uremic syndrome.
    Kavanagh D; Richards A; Goodship T; Jalanko H
    Semin Thromb Hemost; 2010 Sep; 36(6):653-9. PubMed ID: 20865642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
    Giordano M; Castellano G; Messina G; Divella C; Bellantuono R; Puteo F; Colella V; Depalo T; Gesualdo L
    Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More on eculizumab for congenital atypical hemolytic-uremic syndrome.
    Shin JI; Lee JS
    N Engl J Med; 2009 May; 360(20):2142-3; author reply 2143. PubMed ID: 19439754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.